Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

Shire launches digital ‘paper planes’ for rare disease campaign

#FlyForMPS allows supporters to track the miles their plane travels

Novartis Gehry Building

Novartis pushes the accelerator with new Entresto trials

Looks to kick-start sales of its heart failure drug with new study programme

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

Focus on immunotherapies: special magazine from Blue Latitude Health

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear...

Blue Latitude Health

- PMLiVE

Strategic North appoints head of consulting

Simon Campling joins the healthcare strategy agency

- PMLiVE

OPEN Health acquires Choice Healthcare Solutions

Will rebrand the agency under its Succinct agency offering

- PMLiVE

Healthcare costs

The technology poised to drive down the cost of healthcare

- PMLiVE

Catalyx and Health Agency form strategic partnership

Will create targeted healthcare campaigns with crowdsourced intelligence

- PMLiVE

Novartis funds chronic urticaria app and patient community

My Hives has been developed, and will be run, by Exco InTouch

Roche Basel Switzerland

Roche gets first approval for PD-L1 inhibitor Tecentriq

Expects to launch bladder cancer treatment within the next two weeks

Novartis day

Trial sets up showdown between Ibrance and Novartis’ ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval

- PMLiVE

Celgene launches ‘edu-tainment’ psoriasis awareness initiative

Millefeuille film seeks to highlight everyday burden of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links